Work

An integrated population pharmacokinetic/pharmacodynamic (popPK/PD) model to select the linvoseltamab (LINVO) dosing regimen in patients with high-risk smoldering multiple myeloma (HR-SMM).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.7525

Authors: Brett Matzuka, Anasuya Hazra, Sheila Masinde, Lutz Harnisch, John Davis, Paula Rodríguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Anita Boyapati, Yoon Jin, Glenn Scott Kroog, Shawn Sarkaria, Jacob Glass, Jason Chittenden

Institutions: Regeneron (United States), Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Regeneron Pharmaceuticals

OpenAlex ID: W7162496082

Cites:

Cited by:

Related to: